European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
2016/02/10 by L Gossec, Laure Gossec, Josef S Smolen +65 · 29 citations
Medicine · Immunology and Microbiology · #Spondyloarthritis Studies and Treatments #Rheumatoid Arthritis Research and Therapies #Psoriasis: Treatment and Pathogenesis
paper · pdf · doi:10.1136/annrheumdis-2015-208337
Cited by
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
- IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. [europepmc]
- Psoriatic arthritis: state of the art review. [europepmc]
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. [europepmc]
- Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). [europepmc]
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. [europepmc]
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. [europepmc]
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. [europepmc]
- Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. [europepmc]
- French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. [europepmc]
- Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. [europepmc]
- Era of biosimilars in rheumatology: reshaping the healthcare environment. [europepmc]
- Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. [europepmc]
- A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. [europepmc]
- Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. [europepmc]
- Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. [europepmc]
- Treatment guidelines in psoriatic arthritis. [europepmc]
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. [europepmc]
- Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. [europepmc]
- Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. [europepmc]
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. [europepmc]
- Treatment persistence of biologics among patients with psoriatic arthritis. [europepmc]
- The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. [europepmc]
- Layered dissolving microneedles as a need-based delivery system to simultaneously alleviate skin and joint lesions in psoriatic arthritis. [europepmc]
- Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. [europepmc]
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. [europepmc]